Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 4/20 | 0.64 |
| ▸ | TK1 | P04183 | 3/20 | 0.56 |
| ▸ | TERT | O14746 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25896349 | 1.00 | DTYMK (0.64) | DTYMKTK1TERTF2 | |
| SCHEMBL21299317 | 0.94 | DTYMK (0.63) | DTYMKTK1TERTF2 | |
| SCHEMBL21299324 | 0.93 | DTYMK (0.60) | DTYMKTK1TERTF2 | |
| SCHEMBL17268344 | 0.92 | DTYMK (0.74) | DTYMKTK1TERTF2 | |
| SCHEMBL8612856 | 0.92 | DTYMK (0.74) | DTYMKTK1TERTF2 | |
| SCHEMBL8613042 | 0.92 | DTYMK (0.74) | DTYMKTK1TERTF2 | |
| SCHEMBL25895079 | 0.92 | DTYMK (0.70) | DTYMKF2 | |
| SCHEMBL25896356 | 0.92 | DTYMK (0.70) | DTYMKF2 | |
| SCHEMBL29362454 | 0.92 | DTYMK (0.75) | DTYMKTK1TERTF2 | |
| SCHEMBL29607650 | 0.92 | DTYMK (0.75) | DTYMKTK1TERTF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226025-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | MMAB, NSUN3, MSH6 | DTYMK 133/4885TK1 1136/4885TERT 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.